McKesson Europe AG (CAKFY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
McKesson Europe AG (CAKFY) trades at $4.10 with AI Score 35/100 (Grade D). McKesson Europe AG provides pharmaceutical distribution and retail pharmacy services across Europe. Market cap: $5.37B, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for CAKFY: CAKFY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CAKFY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CAKFY: 1/1 perspectives are bearish.
McKesson Europe AG (CAKFY) Healthcare & Pipeline Overview
McKesson Europe AG, a subsidiary of McKesson Corporation, is a major player in the European pharmaceutical distribution and retail pharmacy sectors. Operating through a network of wholesale branches, distribution centers, and retail pharmacies, the company provides pharmaceutical products, healthcare services, and pharmacy management solutions across multiple European countries.
What Is the Investment Thesis for CAKFY?
McKesson Europe AG presents a complex investment case. The company's extensive distribution network and retail pharmacy presence across Europe provide a stable revenue base. However, the company's negative profit margin of -0.5% and a high P/E ratio of -73.27 raise concerns about profitability. Growth catalysts include expanding e-commerce and home care services. Key risks include regulatory changes in the pharmaceutical industry and competition from other distributors. Investors should closely monitor the company's efforts to improve profitability and adapt to evolving market dynamics.
Based on FMP financials and quantitative analysis
CAKFY Key Highlights
- Operates approximately 2,000 owned pharmacies and supports 8,000 members in its brand partnership program, indicating a strong retail presence.
- Serves approximately 40,000 pharmacies and hospitals through its 90 wholesale branches, showcasing a wide distribution network.
- Profit Margin is -0.5%, indicating potential challenges in achieving profitability.
- P/E ratio is -73.27, reflecting the company's current earnings situation.
- Beta of 0.13 suggests low volatility compared to the overall market.
Who Are CAKFY's Competitors?
Who Are CAKFY's Competitors?
CAKFY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ABCZF Abcam plc | $22.25 | +0.68% | $5.12B | 46 |
| ANHGY Mediclinic International plc | $5.49 | +0.00% | $4.05B | 44 |
| ASPHF Ascentage Pharma Group International | $4.53 | -3.51% | $1.69B | 51 |
| DCHPF Dechra Pharmaceuticals PLC | $46.90 | -0.21% | $5.34B | 48 |
| FCAMX Franklin California High Yield Municipal Fund Class A1 | $9.73 | +0.00% | $3.29B | 51 |
| SIXD AllianzIM U.S. Equity 6 Month Buffer10 Jun/Dec ETF | $30.47 | -0.37% | $33.18M | 50 |
| FEDDX Fidelity Emerging Markets Discovery Fd | $22.09 | -0.63% | $1.51B | 47 |
| COWZ Pacer US Cash Cows 100 ETF | $63.41 | -0.48% | $18.33B | 47 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CAKFY's Key Strengths?
- Extensive distribution network across Europe.
- Strong retail pharmacy presence with the Lloyds Pharmacy brand.
- Established relationships with pharmacies and hospitals.
- Part of the global McKesson Corporation.
What Are CAKFY's Weaknesses?
- Negative profit margin.
- High P/E ratio.
- Exposure to regulatory changes in the pharmaceutical industry.
- Dependence on the European market.
What Could Drive CAKFY Stock Higher?
- Expansion of e-commerce and home care services to drive revenue growth.
- Strategic partnerships and acquisitions to expand market presence.
- Development of value-added services for pharmacists to strengthen customer relationships.
- Geographic expansion within Europe to increase market share.
- Focus on specialty pharmaceuticals to capitalize on the growing market.
What Are the Key Risks for CAKFY?
- Increasing competition from other pharmaceutical distributors and retail pharmacy chains.
- Pricing pressures from governments and healthcare providers.
- Economic downturn in Europe affecting consumer spending on healthcare products.
- Disruptions in the supply chain impacting the availability of pharmaceutical products.
- Regulatory changes in the pharmaceutical industry impacting pricing and distribution.
What Are the Growth Opportunities for CAKFY?
- Expansion of E-commerce and Home Care Services: McKesson Europe AG can capitalize on the growing demand for online pharmacy services and home healthcare. The e-commerce market in Europe is projected to reach $200 billion by 2028, offering a significant growth opportunity. By expanding its online platform and home care offerings, McKesson Europe AG can reach a wider customer base and increase revenue streams. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with healthcare providers and acquiring smaller pharmacy chains can expand McKesson Europe AG's market presence and service offerings. The company can leverage partnerships to offer integrated healthcare solutions and enhance customer loyalty. Timeline: Ongoing.
- Development of Value-Added Services for Pharmacists: McKesson Europe AG can further develop and expand its services for pharmacists, such as pharmacy cooperation programs and management tools. By providing value-added services, the company can strengthen its relationships with pharmacists and increase its market share. Timeline: Ongoing.
- Geographic Expansion within Europe: Expanding into new geographic markets within Europe can drive growth for McKesson Europe AG. By entering underserved markets or acquiring existing pharmacy chains, the company can increase its revenue and market share. Timeline: Ongoing.
- Focus on Specialty Pharmaceuticals: The market for specialty pharmaceuticals is growing rapidly, driven by the development of new and innovative therapies. McKesson Europe AG can focus on distributing specialty pharmaceuticals and providing related services to capitalize on this trend. Timeline: Ongoing.
What Opportunities Does CAKFY Have?
- Expansion of e-commerce and home care services.
- Strategic partnerships and acquisitions.
- Development of value-added services for pharmacists.
- Growth in the specialty pharmaceuticals market.
What Threats Does CAKFY Face?
- Increasing competition from other pharmaceutical distributors and retail pharmacy chains.
- Pricing pressures from governments and healthcare providers.
- Economic downturn in Europe.
- Disruptions in the supply chain.
What Are CAKFY's Competitive Advantages?
- Extensive Distribution Network: Operates a large network of wholesale branches and distribution centers across Europe.
- Strong Retail Pharmacy Presence: Operates a significant number of retail pharmacies under the Lloyds Pharmacy brand.
- Established Brand Reputation: Has a long history and established brand reputation in the European pharmaceutical market.
- Part of McKesson Corporation: Benefits from the resources and expertise of its parent company, McKesson Corporation.
What Does CAKFY Do?
McKesson Europe AG, formerly known as Celesio AG, traces its roots back to 1835 and is headquartered in Stuttgart, Germany. The company changed its name in September 2017 after becoming a subsidiary of McKesson Corporation. McKesson Europe AG operates in the pharmaceutical and healthcare sectors, providing logistics and other services. It has two primary divisions: Pharmaceutical Distribution and Retail Pharmacy. The Pharmaceutical Distribution division is involved in the wholesale of pharmaceutical and healthcare products, serving approximately 40,000 pharmacies and hospitals through 90 wholesale branches and operating 70 distribution centers across Europe. The Retail Pharmacy division operates around 2,000 owned pharmacies and has approximately 8,000 members in its brand partnership program. This division provides outpatient drug, e-commerce, and home care services, primarily under the Lloyds Pharmacy brand in countries like Belgium, Ireland, Italy, and the United Kingdom. The division offers traditional prescription drugs, over-the-counter products, and medical services. McKesson Europe AG also provides services for pharmacists, including the organization and management of pharmacy cooperation programs in Great Britain, France, Portugal, and Belgium.
What Products and Services Does CAKFY Offer?
- Wholesale distribution of pharmaceutical products to pharmacies and hospitals.
- Operation of retail pharmacies under the Lloyds Pharmacy brand.
- Provision of outpatient drug services.
- E-commerce services for pharmaceutical products.
- Home care services.
- Management of pharmacy cooperation programs.
- Distribution of traditional prescription drugs and over-the-counter products.
- Provision of medical services.
How Does CAKFY Make Money?
- Generates revenue through the wholesale distribution of pharmaceutical products.
- Earns revenue from the operation of retail pharmacies and the sale of prescription and over-the-counter drugs.
- Provides e-commerce services, generating revenue through online sales.
- Offers home care services, generating revenue through service fees.
What Industry Does CAKFY Operate In?
McKesson Europe AG operates in the competitive pharmaceutical distribution and retail pharmacy industry. The industry is characterized by increasing demand for healthcare services, driven by an aging population and rising prevalence of chronic diseases. Key trends include the growth of e-commerce and home care services, as well as increasing regulatory scrutiny. McKesson Europe AG competes with other major distributors and retail pharmacy chains, such as ABCZF (All American Healthcare Corp), ANHGY (Anthem Inc), ARHCF (Arches Health Care, Inc.), ASPHF (Aspen Healthcare Inc), and DCHPF (Direct Communication Healthcare).
Who Are CAKFY's Key Customers?
- Pharmacies: Supplies pharmaceutical products to approximately 40,000 pharmacies.
- Hospitals: Distributes pharmaceutical products to hospitals.
- Individual Patients: Serves patients through its retail pharmacies and e-commerce platform.
- Pharmacists: Provides services and support to pharmacists through its pharmacy cooperation programs.
CAKFY Financials
CAKFY Latest News
No recent news available for CAKFY.
CAKFY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CAKFY.
Price Targets
Wall Street price target analysis for CAKFY.
CAKFY MoonshotScore
What does this score mean?
The MoonshotScore rates CAKFY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Tilo Köster
Managing Director
Information on Tilo Köster's background is limited. He currently serves as Managing Director of McKesson Europe AG, overseeing the company's operations across its Pharmaceutical Distribution and Retail Pharmacy divisions. His responsibilities include managing a large workforce of over 26,000 employees and driving the company's strategic initiatives in the European market.
Track Record: Due to limited information, Tilo Köster's specific achievements and strategic decisions at McKesson Europe AG are not readily available. His leadership is focused on navigating the complexities of the European pharmaceutical market and driving growth through strategic partnerships and operational efficiencies.
CAKFY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that McKesson Europe AG (CAKFY) may not meet the minimum financial or regulatory requirements for higher tiers like OTCQX or OTCQB. Companies on this tier may have limited reporting requirements, leading to less transparency for investors compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with distressed financials, shell corporations, or those that choose not to comply with stricter reporting standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Transparency: OTC Other companies often have minimal reporting requirements, making it difficult to assess their financial health.
- Low Liquidity: Low trading volume can lead to wide bid-ask spreads and difficulty in executing trades.
- Price Volatility: The lack of liquidity can result in significant price swings.
- Potential for Fraud: The lower regulatory oversight increases the risk of fraudulent activities.
- Delisting Risk: The company may not meet the requirements for listing on higher tiers or major exchanges.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC Other companies.
- Consult with a financial advisor.
- Check for any legal or regulatory issues.
- Subsidiary of McKesson Corporation: Being a subsidiary of a well-established company like McKesson Corporation provides some level of assurance.
- Operational Business: The company has a clear business model and operates in the pharmaceutical distribution and retail pharmacy sectors.
- Employee Count: The company employs over 26,000 people, suggesting a significant operational scale.
- Long Operating History: The company was founded in 1835, indicating a long history in the industry.
CAKFY Healthcare Stock FAQ
What does McKesson Europe AG do?
McKesson Europe AG operates in the pharmaceutical distribution and retail pharmacy sectors across Europe. It distributes pharmaceutical products to approximately 40,000 pharmacies and hospitals through its extensive wholesale network. Additionally, it operates around 2,000 retail pharmacies under the Lloyds Pharmacy brand, providing prescription drugs, over-the-counter products, and medical services to individual patients. The company also offers e-commerce and home care services, as well as pharmacy management solutions for pharmacists.
What do analysts say about CAKFY stock?
As of March 16, 2026, a comprehensive analyst consensus for CAKFY is not readily available due to its OTC listing and limited coverage. Key valuation metrics include a negative profit margin of -0.5% and a P/E ratio of -73.27. Growth considerations center on the company's ability to expand its e-commerce and home care services, as well as its strategic partnerships and acquisitions. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks.
What are the main risks for CAKFY?
The main risks for McKesson Europe AG include increasing competition in the pharmaceutical distribution and retail pharmacy sectors, pricing pressures from governments and healthcare providers, and potential economic downturns in Europe. Additionally, regulatory changes in the pharmaceutical industry and disruptions in the supply chain could impact the company's operations and profitability. As an OTC-listed company, CAKFY also faces risks related to limited transparency, low liquidity, and potential price volatility.
What are the key factors to evaluate for CAKFY?
McKesson Europe AG (CAKFY) currently holds an AI score of 35/100, indicating low score. Key strength: Extensive distribution network across Europe. Primary risk to monitor: Increasing competition from other pharmaceutical distributors and retail pharmacy chains. This is not financial advice.
How frequently does CAKFY data refresh on this page?
CAKFY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CAKFY's recent stock price performance?
Recent price movement in McKesson Europe AG (CAKFY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Extensive distribution network across Europe. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CAKFY overvalued or undervalued right now?
Determining whether McKesson Europe AG (CAKFY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CAKFY?
Before investing in McKesson Europe AG (CAKFY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be limited due to the company's OTC listing.
- Financial data is as of the latest available reporting period.